Is TMS' Cangrelor A CHAMPION After All? "Noise On The Line" Confounded Endpoint Data, CEO Says
This article was originally published in The Pink Sheet Daily
Executive Summary
Speeding heart attack patients into the PCI lab may have blurred the timeline on their MIs and botched endpoint data, says Meanwell.
You may also be interested in...
Cangrelor’s Approval Prospects: FDA Reviewers Say Yes, Team Leader Says No
As The Medicines Co.’s anticlotting drug heads to the Cardiovascular and Renal Drugs Advisory Committee, questions about comparator dosing and timing and the severity of bleeding events will be on the agenda.
The Medicines Co.’s Cangrelor’s Full CHAMPION PHOENIX Results Bode Well For Filing
After two failed studies, The Medicines Co.’s rapid-acting I.V. antiplatelet drug reduces events by more than 20% in the Phase III CHAMPION PHOENIX angioplasty trial against Plavix. However, the company is already facing demand for studies against the newer and more potent antiplatelet drugs Brilinta and Effient.
The Medicines Co.’s Cangrelor’s Full CHAMPION PHOENIX Results Bode Well For Filing
After two failed studies, The Medicines Co.’s rapid-acting IV antiplatelet drug reduces events by more than 20% in the Phase III CHAMPION PHOENIX angioplasty trial against Plavix. However, the company is already facing demand for studies against the newer and more potent antiplatelet drugs Brilinta and Effient.